IPO Mania fizzles disappear in Hong Kong as Mega First-Day Pops

Hong Kong Stock Exchange as LSE bid from Stock Exchange by further setback

Photographer: Paul Yeung / Bloomberg

The days of the massive first-day pop in Hong Kong’s initial public frenzy may be coming to an end.

Although the pandemic spread during most of 2020, the IPOs abroad and new listings of the Chinese city were very popular with both institutional and mother-and-pop investors. Since the bulk of new stock sales made big gains on their first day of trading, investor euphoria was justified.

That was then. Last year’s largely weeping investor game of stacking up and leaving IPOs after making their debut is no longer a bad blow: 31% of thirteen IPOs with more than $ 100 million incurred first-day losses this year yielded, almost double the 17% in 2020. according to data compiled by Bloomberg, the first-day move in 2021 showed a 2.1% increase in 2021 compared to 5.7% last year.

According to investors, the volatility caused by the large conversion into previously unfavorable equities is sensitive to economic fluctuations due to highly valued technology and healthcare games. Others also pointed to concerns about tightening policy in China, as it weighs investors’ risk appetite for new stocks.

Hong Kong's Hang Seng Tech Index had its biggest sales in a year this month

“Most IPOs have performed really strongly last year, but I do not expect this kind of movement this year,” said Joohee An, a fund manager at Mirae Asset Global Invest (HK) Ltd. Investors will be “smarter” market liquidity “will not be as plentiful as before”, she added.

Hong Kong bankers work 24 hours a day as IPOs, SPACs Surge (1)

Wobbly Performance

To be clear, list by Kuaishou Technology and New Horizon Health Ltd. performed exceptionally well in February, with shares more than doubling on the first day.

But the lukewarm performances after the listing are increasing. Chinese household insecticide company Cheerwin Group Ltd. fell by as much as 20% on its first trading day last week. The biopharmaceutical company SciClone Pharmaceuticals Holdings Ltd. ended its debut home on March 3 and now trades 8.6% below its offer price.

The secondary listing wave of U.S. listed Chinese companies has not always had glowing debuts in Hong Kong. Autohome Inc., a Chinese online sales site with its primary listing in New York, has terminated its Hong Kong debut Monday with a modest 2% rise.

.Source